期刊
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
卷 38, 期 1, 页码 294-308出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2022.2147164
关键词
Thymol; pyrazole; anti-inflammatory; COX-2; 5-LOX
New thymol - 1,5-disubstitutedpyrazole hybrids were synthesized as dual COX-2/5-LOX inhibitors. Several compounds displayed inhibitory activity comparable to celecoxib and higher than quercetin, both in vitro and in vivo. Additionally, these compounds showed superior gastrointestinal safety profile.
New thymol - 1,5-disubstitutedpyrazole hybrids were synthesised as dual COX-2/5-LOX inhibitors. Compounds 8b, 8g, 8c, and 4a displayed in vitro inhibitory activity against COX-2 (IC50 = 0.043, 0.045, 0.063, and 0.068 mu M) nearly equal to celecoxib (IC50 = 0.045 mu M) with high SI (316, 268, 204, and 151, respectively) comparable to celecoxib (327). All target compounds, 4a-c and 8a-i, showed in vitro 5-LOX inhibitory activity higher than reference quercetin. Besides, they possessed in vivo inhibition of formalin-induced paw oedema higher than celecoxib. In addition, compounds 4a, 4b, 8b, and 8g showed superior gastrointestinal safety profile (no ulceration) as celecoxib and diclofenac sodium in the population of fasted rats. In conclusion, compounds 4a, 8b, and 8g achieved the target goal. They elicited in vitro dual inhibition of COX-2/5-LOX higher than celecoxib and quercetin, in vivo potent anti-inflammatory activity higher than celecoxib and in vivo superior gastrointestinal safety profile (no ulceration) as celecoxib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据